Compare Novavax Inc (NVAX) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Oklo Inc — how do they compare? Novavax Inc trades at $12.94 (market cap $1.82B), while Oklo Inc trades at $34.68 (market cap $6.43B). The key difference: Oklo Inc is far larger — about 3.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Oklo Inc for 32 Days on average.
| NVAX | OKLO | |
|---|---|---|
Market Cap | $1.82B | $6.43B |
Volume | 6,198,505 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $12.56 | $174.14 |
52-Week Low | $6.22 | $34.57 |
Typical Hold Time | 59 Days | 32 Days |
Enterprise Value | $1.39B | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
OKLO trades at $34.65, down 5.91% today, with a bearish technical signal from moving averages. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Analyst consensus remains strongly bullish with a $78.63 price target, but recent news highlights competitive pressures and dilution concerns from stock sales.
The outlook hinges on OKLO's ability to commercialize its nuclear reactor pipeline. High institutional buy ratings suggest long-term potential, but execution risks, cash burn, and intense competition in the SMR space pose significant challenges. The stock offers speculative growth exposure amid substantial operational and financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
